800.04 Early Clinical Outcomes Associated with the Sapien 3 Ultra Resilia Valve Compared to the Sapien 3 and Sapien 3 Ultra Valves

C.T. Stinis,A. Abbas,P. Teirstein,R. Makkar,C.J. Chung,V. Iyer,P. Genereux,R.M. Kipperman,J.K. Harrison,G.C. Hughes,J.M. Lyons,A. Rahman,N. Kakouros,J. Walker,D.K. Roberts,P.-H. Huang,B. Kar,A. Dhoble,D.P. Logsdon,P. Khanna,J. Aragon,J.M. McCabe
DOI: https://doi.org/10.1016/j.jcin.2024.01.229
IF: 11.075
2024-02-28
JACC Cardiovascular Interventions
Abstract:The SAPIEN 3 Ultra Resilia valve (S3UR, Edwards Lifesciences, Irvine, CA) incorporates several design changes as compared to its predecessors, the SAPIEN 3 (S3) and SAPIEN 3 Ultra valves (S3U), including bovine leaflets treated with a novel process intended to minimize leaflet calcification and thereby reduce structural valve deterioration, as well as a taller external skirt on the 29mm valve size intended to reduce paravalvular leak (PVL). The clinical performance of S3UR compared to S3 and
cardiac & cardiovascular systems
What problem does this paper attempt to address?